Enovis (NYSE:ENOV) Director Sharon Wienbar Buys 900 Shares of Stock

Enovis Corporation (NYSE:ENOV) Director Sharon Wienbar acquired 900 shares of Enovis stock in a transaction that occurred on Wednesday, November 11th. The stock was purchased at an average price of $27.76 per share, with a total value of $24,984.00. Following the transaction, the director owned 45,551 shares of the company’s stock, valued at $1,264,495.76. This trade represents a 2.02% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Enovis Trading Down 3.2%

NYSE:ENOV opened at $27.63 on Friday. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.08 and a current ratio of 2.15. Enovis Corporation has a 1 year low of $16.70 and a 1 year high of $31.81. The stock has a market capitalization of $1.59 billion, a price-to-earnings ratio of -3.00 and a beta of 1.31. The stock has a fifty day moving average price of $20.36 and a two-hundred day moving average price of $23.19.

Enovis (NYSE:ENOV) last posted its quarterly earnings results on Thursday, November 5th. The company reported $0.88 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.77 by $0.11. The company had revenue of $558.73 million during the quarter, compared to the consensus estimate of $557.12 million. Enovis had a negative net margin of 22.86% and a positive return on equity of 13.23%. The company’s revenue for the quarter was up 1.8% on a year-over-year basis. During the same period last year, the firm earned $0.75 EPS. As a group, sell-side analysts anticipate that Enovis Corporation will post 3.15 earnings per share for the current fiscal year.

Key Enovis News

Here’s some of the latest news about ENOV:

• Positive Sentiment: Directors Angela S. Lalor and Sharon L. Wienbar reported purchases on November 10 and 11, totaling 3,531 shares worth about $100,000. The buying may bolster investor confidence, although the transactions are relatively modest and do not guarantee future performance. Lalor SEC filing Wienbar SEC filing
• Neutral Sentiment: Enovis said management will present at the Jefferies Global Healthcare Conference in London on November 17. The announcement provides an opportunity for investors to hear from management but disclosed no new financial guidance or business developments. Conference announcement

Institutional Investors Weigh In On Enovis

Several hedge funds have recently modified their holdings of ENOV. Bank of America Corp DE purchased a new stake in shares of Enovis during the 2nd quarter valued at $11,502,000. First National Bank of Omaha acquired a new position in shares of Enovis during the 2nd quarter valued at $1,250,000. Legal & General Group Plc acquired a new position in shares of Enovis during the 2nd quarter valued at $2,753,000. Man Group plc purchased a new stake in Enovis during the 2nd quarter worth $8,711,000. Finally, Jupiter Topco LLC purchased a new stake in Enovis during the 2nd quarter worth $2,346,000. 98.45% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on ENOV shares. Citigroup reissued a “market outperform” rating on shares of Enovis in a research note on Wednesday, September 2nd. Wells Fargo & Company upped their target price on Enovis from $33.00 to $37.00 and gave the company an “overweight” rating in a research note on Friday, November 6th. Needham & Company LLC raised their price target on Enovis from $34.00 to $38.00 and gave the stock a “buy” rating in a research report on Thursday, November 5th. Weiss Ratings raised Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, November 2nd. Finally, Canaccord Genuity Group cut their price target on Enovis from $45.00 to $42.00 and set a “buy” rating for the company in a report on Friday, November 6th. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $38.62.

Enovis Company Profile

Enovis is a medical technology company that develops products and solutions for orthopedic care, surgery, recovery and rehabilitation. Its offerings include joint replacement implants, foot and ankle products, surgical instruments, orthopedic braces and supports, and rehabilitation equipment. The company serves healthcare providers and patients in markets around the world. Its products are designed to support treatment across different stages of musculoskeletal care, from surgical intervention to recovery and mobility.